Cancer Research and Treatment

Original Articles

Combination of TRAP1 and ERCC1 Expression Predicts Clinical Outcomes in Metastatic Colorectal Cancer Treated with Oxaliplatin/5-Fluorouracil: Jae Joon Han, Sun Kyung Baek, Jae Jin Lee, Gou Young Kim, Si-Young Kim, Suk-Hwan Lee; Cancer Res Treat. 2014;46(1):55-64. Published online January 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.1.55

PURPOSE
The novel heat shock protein tumor necrosis factor receptor-associated protein 1 (TRAP1) is associated with multidrug resistance in colorectal cancer (CRC) cells in vitro. Excision repair cross-complementation group 1 (ERCC1) expression levels in tumor tissues also predict clinical outcomes in metastatic CRC patients receiving combination oxaliplatin and 5-fluorouracil treatment. We investigated whether TRAP1 and ERCC1 protein expression by immunohistochemistry predict clinical outcomes in CRC patients.
MATERIALS AND METHODS
The study population consisted of 56 patients with metastatic CRC who received first-line oxaliplatin/5-fluorouracil therapy. Clinical response and overall survival (OS) by levels of the markers TRAP1 and ERCC1 were evaluated.
RESULTS
The rates of TRAP1 and ERCC1 expression were 21% and 52%, respectively. Patients negative for ERCC1 expression showed a tendency to respond to chemotherapy (p=0.066). Median OS was significantly longer in patients negative for TRAP1 than those positive for TRAP1 (p=0.023). Patients negative for ERCC1 expression also had a better OS than those positive for ERCC1 (p=0.021). The median OS was 30.9 months for patients negative for TRAP1 and ERCC1 compared to 13.2 months for those positive for TRAP1 and/or positive for ERCC1 expression (p=0.006). The combination of TRAP1 and ERCC1 expression was significantly associated with the response to chemotherapy (p=0.046) and independently predicted median OS in multivariate analysis (hazard ratio, 2.98; 95% confidence interval, 1.18 to 7.49).
CONCLUSION
The present study demonstrates that the combination of TRAP1 and ERCC1 expression predicts the survival of metastatic CRC patients who were treated with oxaliplatin/5-fluorouracil.

Citations

Citations to this article as recorded by

Mitochondria: a crucial factor in the progression and drug resistance of colorectal cancer
Ying Zhao, Xiaomin Guo, Li Zhang, Dongwei Wang, Yan Li
Frontiers in Immunology.2024;[Epub] CrossRef
New insights into molecular chaperone TRAP1 as a feasible target for future cancer treatments
Xiao-Tong Li, Ying-Shuang Li, Zhao-Yu Shi, Xiu-Li Guo
Life Sciences.2020; 254: 117737. CrossRef
Gene Copy Number and Post-Transductional Mechanisms Regulate TRAP1 Expression in Human Colorectal Carcinomas
Michele Pietrafesa, Francesca Maddalena, Luciana Possidente, Valentina Condelli, Pietro Zoppoli, Valeria Li Bergolis, Maria Grazia Rodriquenz, Michele Aieta, Giulia Vita, Franca Esposito, Matteo Landriscina
International Journal of Molecular Sciences.2019; 21(1): 145. CrossRef
HSPA1A, HSPA1L and TRAP1 heat shock genes may be associated with prognosis in ovarian epithelial cancer
Warne De Andrade, Let�cia Braga, Nikole Gon�ales, Luciana Silva, Agnaldo Da Silva Filho
Oncology Letters.2019;[Epub] CrossRef
Trps1 is associated with the multidrug resistance of lung cancer cell by regulating MGMT gene expression
Hongxiang Liu, Yi Liao, Meng Tang, Tao Wu, Deli Tan, Shixin Zhang, Haidong Wang
Cancer Medicine.2018; 7(5): 1921. CrossRef
Clinical importance of DNA repair in sporadic colorectal cancer
Gustavo A. Laporte, Natalia M. Leguisamo, Antonio N. Kalil, Jenifer Saffi
Critical Reviews in Oncology/Hematology.2018; 126: 168. CrossRef
Expression of DDB2 Protein in the Initiation, Progression, and Prognosis of Colorectal Cancer
Huaiwei Yang, Jingwei Liu, Jingjing Jing, Zeyang Wang, Yi Li, Kaihua Gou, Xue Feng, Yuan Yuan, Chengzhong Xing
Digestive Diseases and Sciences.2018; 63(11): 2959. CrossRef
Thymidylate synthase expression in primary colorectal cancer as a predictive marker for the response to 5‑fluorouracil‑ and oxaliplatin‑based preoperative chemotherapy for liver metastases
Hiroshi Takeyama, Tomoko Wakasa, Keisuke Inoue, Kotaro Kitani, Masanori Tsujie, Takafumi Ogawa, Masao Yukawa, Yoshio Ohta, Masatoshi Inoue
Molecular and Clinical Oncology.2018;[Epub] CrossRef
Clinicopathologic significance of TRAP1 expression in colorectal cancer: a large scale study of human colorectal adenocarcinoma tissues
Min Gyoung Pak, Hyong Jong Koh, Mee Sook Roh
Diagnostic Pathology.2017;[Epub] CrossRef
TRAP1: a viable therapeutic target for future cancer treatments?
Giacomo Lettini, Francesca Maddalena, Lorenza Sisinni, Valentina Condelli, Danilo Swann Matassa, Maria Paola Costi, Daniele Simoni, Franca Esposito, Matteo Landriscina
Expert Opinion on Therapeutic Targets.2017; 21(8): 805. CrossRef
TRAP1 protein signature predicts outcome in human metastatic colorectal carcinoma
Francesca Maddalena, Vittorio Simeon, Giulia Vita, Annamaria Bochicchio, Luciana Possidente, Lorenza Sisinni, Giacomo Lettini, Valentina Condelli, Danilo Swann Matassa, Valeria Li Bergolis, Alberto Fersini, Sante Romito, Michele Aieta, Antonio Ambrosi, Fr
Oncotarget.2017; 8(13): 21229. CrossRef
Nucleotide Excision Repair and Response and Survival to Chemotherapy in Colorectal Cancer Patients
Elisabeth J Kap, Odilia Popanda, Jenny Chang-Claude
Pharmacogenomics.2016; 17(7): 755. CrossRef
TRAP1 regulates cell cycle and apoptosis in thyroid carcinoma cells
Giuseppe Palladino, Tiziana Notarangelo, Giuseppe Pannone, Annamaria Piscazzi, Olga Lamacchia, Lorenza Sisinni, Girolamo Spagnoletti, Paolo Toti, Angela Santoro, Giovanni Storto, Pantaleo Bufo, Mauro Cignarelli, Franca Esposito, Matteo Landriscina
Endocrine-Related Cancer.2016; 23(9): 699. CrossRef
TRAP1 regulates stemness through Wnt/β-catenin pathway in human colorectal carcinoma
Giacomo Lettini, Lorenza Sisinni, Valentina Condelli, Danilo Swann Matassa, Vittorio Simeon, Francesca Maddalena, Marica Gemei, Elvira Lopes, Giulia Vita, Luigi Del Vecchio, Franca Esposito, Matteo Landriscina
Cell Death & Differentiation.2016; 23(11): 1792. CrossRef
TRAP1 downregulation in human ovarian cancer enhances invasion and epithelial–mesenchymal transition
Maria R Amoroso, Danilo S Matassa, Ilenia Agliarulo, Rosario Avolio, Haonan Lu, Lorenza Sisinni, Giacomo Lettini, Hani Gabra, Matteo Landriscina, Franca Esposito
Cell Death & Disease.2016; 7(12): e2522. CrossRef
A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites
Yan Zhang, Junli Ma, Sai Zhang, Ganlu Deng, Xiaoling Wu, Jingxuan He, Haiping Pei, Hong Shen, Shan Zeng
International Journal of Colorectal Disease.2015; 30(9): 1173. CrossRef
TRAP1 revisited: Novel localizations and functions of a ‘next-generation’ biomarker (Review)
MARIA ROSARIA AMOROSO, DANILO SWANN MATASSA, LORENZA SISINNI, GIACOMO LETTINI, MATTEO LANDRISCINA, FRANCA ESPOSITO
International Journal of Oncology.2014; 45(3): 969. CrossRef

12,533 View
104 Download
20 Web of Science
17 Crossref

Effects of the Expression of Leptin and Leptin Receptor (OBR) on the Prognosis of Early-stage Breast Cancers: Yongnam Kim, Si-Young Kim, Jae Jin Lee, Jeongho Seo, Youn-Wha Kim, Suck Hwan Koh, Hwi-Joong Yoon, Kyung Sam Cho; Cancer Res Treat. 2006;38(3):126-132. Published online June 30, 2006; DOI: https://doi.org/10.4143/crt.2006.38.3.126

Abstract PDF PubReader ePub

Purpose

Obesity-related leptin and leptin receptor (OBR) have a relation to the development of cancer and metastasis and also the low survival rate for breast cancer patients. Leptin has been associated with increased aromatase activity and it displays functional cross-talk with estrogen. This study was designed to determine the relationship between the expression of leptin and OBR in breast cancer tissue and the prognosis of early-stage breast cancer patients, and especially for the tamoxifen-treated patients.

Materials and Methods

Ninety-five patients with early-stage breast cancer and who had undergone surgical treatment at Kyung Hee University Hospital between January 1994 and June 2004 were analyzed. The surgical specimens underwent immunohistochemical analysis for leptin and OBR. The patients' survival and clinical characteristics were obtained from the medical records.

Results

Of the 95 patients, 79 (83%) and 32 (33.7%) showed the expression of leptin and OBR in breast cancer tissue, respectively. The expression of leptin and OBR in breast cancer tissue was not significantly related to the clinicopathological characteristics, including obesity, the expression of hormonal receptor, the HER-2/neu expression, menopause, stage and the nuclear grade. The expression of leptin and OBR was not significantly related to the overall disease-free survival (DFS). For the tamoxifen-treated postmenopausal obese patients, the DFS of the leptin-positive group was higher than that of the leptin-negative group (p=0.017).

Conclusion

The expression of leptin and OBR in breast cancer tissue may be not a prognostic factor for disease-free survival of breast cancer patients. In the future, further studies are needed to determine whether leptin expression could be a predictive factor for tamoxifen therapy in the postmenopausal obese subgroup among the early breast cancer patients.

Citations

Citations to this article as recorded by

Exploring the multifaceted role of obesity in breast cancer progression
Sooraj Kakkat, Prabhat Suman, Elba A. Turbat- Herrera, Seema Singh, Debanjan Chakroborty, Chandrani Sarkar
Frontiers in Cell and Developmental Biology.2024;[Epub] CrossRef
Greater Body Fatness Is Associated With Higher Protein Expression of LEPR in Breast Tumor Tissues: A Cross-Sectional Analysis in the Women’s Circle of Health Study
Adana A.M. Llanos, John B. Aremu, Ting-Yuan David Cheng, Wenjin Chen, Marina A. Chekmareva, Elizabeth M. Cespedes Feliciano, Bo Qin, Yong Lin, Coral Omene, Thaer Khoury, Chi-Chen Hong, Song Yao, Christine B. Ambrosone, Elisa V. Bandera, Kitaw Demissie
Frontiers in Endocrinology.2022;[Epub] CrossRef
Association of Serum Leptin with Prognostic Factors in Breast Cancer
Amirreza Hajati, Farshad Talebian, Asrin Babahajian, Nasrin Daneshkhah, Bayazid Ghaderi
Sudan Journal of Medical Sciences.2022; 17(1): 4. CrossRef
Roles and mechanisms of adipokines in drug resistance of tumor cells
Yan Li, Chunyan Yu, Weimin Deng
European Journal of Pharmacology.2021; 899: 174019. CrossRef
Immunohistochemical analysis of adipokine and adipokine receptor expression in the breast tumor microenvironment: associations of lower leptin receptor expression with estrogen receptor-negative status and triple-negative subtype
Adana A. M. Llanos, Yong Lin, Wenjin Chen, Song Yao, Jorden Norin, Marina A. Chekmareva, Coral Omene, Lei Cong, Angela R. Omilian, Thaer Khoury, Chi-Chen Hong, Shridar Ganesan, David J. Foran, Michael Higgins, Christine B. Ambrosone, Elisa V. Bandera, Kit
Breast Cancer Research.2020;[Epub] CrossRef
Leptin signaling axis specifically associates with clinical prognosis and is multifunctional in regulating cancer progression
Tsung-Chieh Lin, Kuan-Wei Huang, Chia-Wei Liu, Yu-Chan Chang, Wei-Ming Lin, Tse-Yen Yang, Michael Hsiao
Oncotarget.2018; 9(24): 17210. CrossRef
Immunohistochemical staining of leptin is associated with grade, stage, lymph node involvement, recurrence, and hormone receptor phenotypes in breast cancer
Mohamad Nidal Khabaz, Amer Abdelrahman, Nadeem Butt, Lila Damnhory, Mohamed Elshal, Alia M. Aldahlawi, Swsan Ashoor, Basim Al-Maghrabi, Pauline Dobson, Barry Brown, Kaltoom Al-Sakkaf, Mohmmad Al-Qahtani, Jaudah Al-Maghrabi
BMC Women's Health.2017;[Epub] CrossRef
Leptin, adipocytes and breast cancer: Focus on inflammation and anti-tumor immunity
Laetitia Delort, Adrien Rossary, Marie-Chantal Farges, Marie-Paule Vasson, Florence Caldefie-Chézet
Life Sciences.2015; 140: 37. CrossRef
Leptine : implication dans la physiopathologie du cancer du sein
Florence Caldefie-Chézet, Virginie Dubois, Laetitia Delort, Adrien Rossary, Marie-Paule Vasson
Annales d'Endocrinologie.2013; 74(2): 90. CrossRef
Serum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs)
Mehmet Artac, Hakan Bozcuk, Aysel Kıyıcı, Orhan Onder Eren, Melih Cem Boruban, Mustafa Ozdogan
Breast Cancer.2013; 20(2): 174. CrossRef
Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer
Xiaofeng Chen, Xiaoming Zha, Wei Chen, Tingting Zhu, Jinrong Qiu, Oluf Dimitri Røe, Jun Li, Zhaoxia Wang, Yongmei Yin
Biomedicine & Pharmacotherapy.2013; 67(1): 22. CrossRef
The role of leptin receptor gene polymorphisms in determining the susceptibility and prognosis of NSCLC in Chinese patients
Yuliang Li, Jianli Geng, Yongzheng Wang, Qinghua Lu, Yimeng Du, Wujie Wang, Zheng Li
Journal of Cancer Research and Clinical Oncology.2012; 138(2): 311. CrossRef
Leptin and breast cancer: an overview
Mehmet Artac, Kadri Altundag
Medical Oncology.2012; 29(3): 1510. CrossRef

11,307 View
44 Download
13 Crossref

Increased ERCC Expression Correlates with Improved Outcome of Patients Treated with Cisplatin as an Adjuvant Therapy for Curatively Resected Gastric Cancer: Sun Kyung Baek, Si-Young Kim, Jae Jin Lee, Yoon Wha Kim, Hwi Joong Yoon, Kyung Sam Cho; Cancer Res Treat. 2006;38(1):19-24. Published online February 28, 2006; DOI: https://doi.org/10.4143/crt.2006.38.1.19

Abstract PDF PubReader ePub

Purpose

It has been reported that the overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is essential for the repair of cisplatin (CDDP)-DNA adducts, negatively influences the effectiveness of CDDP-based therapy for primary gastric cancer. We investigated whether the ERCC1 expression was associated with survival for gastric cancer patients in an adjuvant setting.

Materials and Methods

We retrospectively analyzed 44 patients who were diagnosed with stage II or higher disease after undergoing curative resection and they had also received cisplatin-based chemotherapy. The ERCC1 expression was examined by performing immunohistochemical (IHC) staining, and this was divided into two groups according to the percentage of IHC staining of the tumor cell nuclei (negative: 10% or less, positive: more than 10%).

Results

Among the 44 patients (ERCC1-negative/ERCC1-positive group=16/28), 32 patients were male and their median age was 52 years. There was no difference for the baseline characteristics of the two groups. The median follow-up duration was 41 months. The median disease-free survival (DFS) and the overall survival (OS) for the ERCC1-positive group were significant higher than those of the ERCC1-negative group (DFS: 40.4 vs. 14.6 months, p=0.02, OS: undefined vs. 20.4 months, p=0.008).

Conclusion

The overall survival in gastric cancer patients who received cisplatin-based adjuvant chemotherapy after a curative resection is higher in those patients showing the overexpression of the ERCC1 gene. However, prospective studies using the ERCC1 gene expression as a prognostic marker for the DNA repair activity are needed.

Citations

Citations to this article as recorded by

Somatic mutation of DNAH genes implicated higher chemotherapy response rate in gastric adenocarcinoma patients
Chunchao Zhu, Qin Yang, Jia Xu, Wenyi Zhao, Zizhen Zhang, Danhua Xu, Yeqian Zhang, Enhao Zhao, Gang Zhao
Journal of Translational Medicine.2019;[Epub] CrossRef
The design, analysis and application of mouse clinical trials in oncology drug development
Sheng Guo, Xiaoqian Jiang, Binchen Mao, Qi-Xiang Li
BMC Cancer.2019;[Epub] CrossRef
Methods and significance of the combined detection of HER2 gene amplification and chemosensitivity in gastric cancer
Yang-Kun Wang, Su-Nan Wang, Ying-Ying Li, Gong-Ping Wang, Tian Yun, Chao-Ya Zhu, Bin-Feng Yang, Cong-Yang Li, Bo Jiang, Mei-Ling Zhu
Cancer Biomarkers.2018; 21(2): 439. CrossRef
The Profile of Serum microRNAs Predicts Prognosis for Resected Gastric Cancer Patients Receiving Platinum-Based Chemotherapy
Jianning Song, Jie Yin, Zhigang Bai, Jun Zhang, Hua Meng, Jun Cai, Wei Deng, Xuemei Ma, Zhongtao Zhang
Digestive Diseases and Sciences.2017; 62(5): 1223. CrossRef
Haplotype analysis on relationship of ERCC2 and ERCC3 gene polymorphisms with osteosarcoma risk in Chinese young population
Qiang Xu, Zuofu Zhang, Weixue Sun, Baiqiang Hu
Mammalian Genome.2017; 28(5-6): 227. CrossRef
Prognostic value of excision repair cross-complementation group 1 expression in gastric cancer: A meta-analysis
PENG SONG, QIN YIN, MING LU, BO FU, BAOLIN WANG, QINGHONG ZHAO
Experimental and Therapeutic Medicine.2015; 9(4): 1393. CrossRef
Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: a meta-analysis
Anqi Yao, You Wang, Xiaohong Peng, Rong Ye, Qiaoli Wang, Yuexiao Qi, Fuxiang Zhou
Journal of Cancer Research and Clinical Oncology.2014; 140(12): 2107. CrossRef
Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer
Yalei Zhang, Haihong Yang, Yuan Qiu, Qiuhua Deng, Jun Liu, Meiling Zhao, Ping He, Mingcong Mo, Xusen Zou, Jianxing He
Medical Oncology.2014;[Epub] CrossRef
The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis
Kong-Kong Wei, Lei Jiang, Yao-Yao Wei, Yu-Feng Wang, Xuan-Kun Qian, Qiang Dai, Quan-Lin Guan
Tumor Biology.2014; 35(9): 8721. CrossRef
ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy
Sara De Dosso, Elena Zanellato, Martina Nucifora, Renzo Boldorini, Angelica Sonzogni, Roberto Biffi, Nicola Fazio, Eraldo Bucci, Ottavio Beretta, Stefano Crippa, Piercarlo Saletti, Milo Frattini
Cancer Chemotherapy and Pharmacology.2013; 72(1): 159. CrossRef
Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma
Malcolm H. Squires, Sarah B. Fisher, Kevin E. Fisher, Sameer H. Patel, David A. Kooby, Bassel F. El‐Rayes, Charles A. Staley, Alton B. Farris, Shishir K. Maithel
Cancer.2013; 119(17): 3242. CrossRef
GSTP1, ERCC1 and ERCC2 Polymorphisms, Expression and Clinical Outcome of Oxaliplatin-based Adjuvant Chemotherapy in Colorectal Cancer in Chinese Population
Hui-Yan Li, Xin Ge, Guang-Ming Huang, Kai-Yu Li, Jing-Quan Zhao, Xi-Miao Yu, Wen-Si Bi, Yu-Lin Wang
Asian Pacific Journal of Cancer Prevention.2012; 13(7): 3465. CrossRef
Association of Four ERCC1 and ERCC2 SNPs with Survival of Bone Tumour Patients
Ting Hao, Wei Feng, Jie Zhang, Yong-Jian Sun, Gang Wang
Asian Pacific Journal of Cancer Prevention.2012; 13(8): 3821. CrossRef
The Real Estate of Gastric Cancer Induction Therapy: Location Versus Intrinsic Molecular Architecture
Roderich E. Schwarz, John C. Mansour
Annals of Surgical Oncology.2012; 19(7): 2081. CrossRef
Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy
Ki Han Kim, Hyuk-Chan Kwon, Sung Yong Oh, Sung Hyun Kim, Suee Lee, Kyung A Kwon, Jin Seok Jang, Min Chan Kim, Su-Jin Kim, Hyo-Jin Kim
Biomarkers.2011; 16(1): 74. CrossRef
ERCC1: Impact in Multimodality Treatment of Upper Gastrointestinal Cancer
Ralf Metzger, Elfriede Bollschweiler, Arnulf H Hölscher, Ute Warnecke-Eberz
Future Oncology.2010; 6(11): 1735. CrossRef
Biomarker analysis in stage III–IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival
J-S Kim, M-A Kim, T M Kim, S-H Lee, D-W Kim, S-A Im, T-Y Kim, W H Kim, H-K Yang, D S Heo, Y-J Bang, K-U Lee, K-J Choe, N K Kim
British Journal of Cancer.2009; 100(5): 732. CrossRef

12,935 View
61 Download
17 Crossref

The Efficacy of a Modified Chronomodulated Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin in Advanced Colorectal Cancer (Preliminary Data): Ji Young Park, Si-Young Kim, Jae Jin Lee, Hwi Joong Yoon, Kyung Sam Cho; Cancer Res Treat. 2004;36(3):199-204. Published online June 30, 2004; DOI: https://doi.org/10.4143/crt.2004.36.3.199

Abstract PDF PubReader ePub

Purpose

To determine the efficacy and tolerability of a modified chronomodulated infusion of oxaliplatin, 5-fluorouracil (5-FU) and leucovorin in the treatment of advanced colorectal cancer.

Materials and Methods

Sixteen patients with relapsed or metastatic colorectal cancer were treated with an intravenous infusion of oxaliplatin 25 mg/m², 5-FU 700 mg/m² and leucovorin 20 mg/m² on days 1 to 5. The infusion of oxaliplatin was chronomodulated with a peak delivery rate at 16:00 p.m., with 5-FU infused constantly overnight. Each course was repeated every 21 days.

Results

The response rate was 38.5% (95% confidence interval [CI], 13.9% to 68.4%) in the 13 measurable patients, including 1 complete response (7.7%) and 4 partial responses (30.8%). Five patients (38.5%) had a stable disease and 3 (23.0%) a progressive disease. Three patients without a measurable lesion had improved status. The median time to progression and overall survival were 29 weeks and 85 weeks, respectively. Grade 3 thrombocytopenia occurred in 2.5% (2 cycles) and grade 3 vomiting in 12.5% (2 patients). Anorexia, stomatitis, diarrhea, pruritus, alopecia and peripheral neuropathy were mild and tolerable.

Conclusion

The modified chronomodulated infusion of oxaliplatin, 5-FU and leucovorin is effective and tolerable, but the number of patients was too small. Further study will be needed to confirm the efficacy of this regimen with a larger population of patients.

Citations

Citations to this article as recorded by

Combination Chemotherapy of Oxaliplatin, 5-Fluorouracil and Low Dose Leucovorin in Patients with Advanced Colorectal Cancer
Yoon Mi Shin, Hae Suk Han, Seong Woo Lim, Byung Chul Kim, Kyung Suck Cheoi, Young Ook Eum, Seung Taek Kim, Ki Hyeong Lee
Cancer Research and Treatment.2005; 37(5): 284. CrossRef

9,494 View
45 Download
1 Crossref

Randomized Phase III Trial of Cisplatin, Epirubicin, Leucovorin, 5-Fluorouracil (PELF) Combination versus 5-fluorouracil Alone as Adjuvant Chemotherapy in Curative Resected Stage III Gastric Cancer: Jae Jin Lee, Si-Young Kim, Im sik Shin, Kyung Sam Cho, Hoong-Zae Joo, Choong Yoon, Yoon Wha Kim, Hwi Joong Yoon; Cancer Res Treat. 2004;36(2):140-145. Published online April 30, 2004; DOI: https://doi.org/10.4143/crt.2004.36.2.140

Abstract PDF PubReader ePub

Purpose

The combination of cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) administration, as adjuvant chemotherapy after curative resection for gastirc cancer, was compared with 5-fluorouracil (5-FU) administration alone. This paper reports the results of a prospective randomized comparison of the two regimens, PELF and 5-FU.

Methods

From August 1996 to July 1999, 54 patients were selected subsequent to being diagnosed with stage III cancer after a curative resection for gastric cancer. The patients were stratified according to stage IIIA/IIIB and subtotal/total gastrectomy, and then they were randomized into each treatment group, i.e. the PELF or 5-FU alone groups.

Results

54 assessable patients were enrolled in this study: 28 received PELF and 26 received 5-FU alone. 12 patients relapsed in each group and the median follow-up duration was 42 months (range: 10~77 months). The overall survival rate and disease-free survival rate (DFS) were not significantly different between two groups, (5-year survival of PELF vs. 5-FU: 57% vs. 64%, 5-year DFS: 54% vs. 51%). The PELF combination was more toxic in terms of anemia, anorexia, nausea and diarrhea than the 5-FU.

Conclusions

This study showed that the PELF combination, as an adjuvant therapy for gastric cancer after a curative resection, was a less effective treatment, and it had more toxic effects than the 5-FU.

Citations

Citations to this article as recorded by

Multidisciplinary treatment strategy for locally advanced gastric cancer: A systematic review
Kotaro Sugawara, Yoshikuni Kawaguchi, Yasuyuki Seto, Jean-Nicolas Vauthey
Surgical Oncology.2021; 38: 101599. CrossRef
The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis
Tom van den Ende, Emil ter Veer, Mélanie Machiels, Rosa M. A. Mali, Frank A. Abe Nijenhuis, Laura de Waal, Marety Laarman, Suzanne S. Gisbertz, Maarten C. C. M. Hulshof, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
Cancers.2019; 11(1): 80. CrossRef
Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis
Tom van den Ende, Emil ter Veer, Rosa M. A. Mali, Mark I. van Berge Henegouwen, Maarten C. C. M. Hulshof, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
Cancers.2019; 11(4): 530. CrossRef
COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis
Tom van den Ende, Frank A. Abe Nijenhuis, Héctor G. van den Boorn, Emil ter Veer, Maarten C. C. M. Hulshof, Suzanne S. Gisbertz, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
Frontiers in Oncology.2019;[Epub] CrossRef
Comparative effectiveness of adjuvant treatments for resected gastric cancer: a network meta-analysis
Zhaolun Cai, Yiqiong Yin, Yuan Yin, Chaoyong Shen, Jian Wang, Xiaonan Yin, Zhixin Chen, Ye Zhou, Bo Zhang
Gastric Cancer.2018; 21(6): 1031. CrossRef
Current challenges of metastatic breast cancer
Bora Lim, Gabriel N. Hortobagyi
Cancer and Metastasis Reviews.2016; 35(4): 495. CrossRef
Management of Gastroesophageal Junction Tumors
Matthew P. Fox, Victor van Berkel
Surgical Clinics of North America.2012; 92(5): 1199. CrossRef

9,822 View
61 Download
7 Crossref

Prognostic Effect of Vascular Endothelial Growth Factor and Angiogenesis in Gastric Carcinoma: Myoung Im Kim, Si Young Kim, Jae Jin Lee, Hwi Joong Yoon, Yoon Wha Kim, Kyung Sam Cho; Cancer Res Treat. 2003;35(3):218-223. Published online June 30, 2003; DOI: https://doi.org/10.4143/crt.2003.35.3.218

Abstract PDF

PURPOSE
Many studies have shown that angiogenesis has an important role in the growth, progression, and metastasis of solid tumors. Recently, several angiogenic factors have been identified. Vascular endothelial growth factor (VEGF) is a well characterized inducer of angiogenesis. In this study, we investigated the prognostic significance of the expression of VEGF in patients with an advanced gastric carcinoma. MATERIALS AND METHODS: Specimens from 54 gastric adenocarcinoma patients were stained using a polyclonal antibody against VEGF. Correlations of the expression of VEGF, microvessel density, and various other clinicopathological factors were analysed. RESULTS: Seventeen (31.5%) and 37 cases (68.5%) were VEGF-negative and positive, respectively. There was significant correlation between the expression of VEGF and pathological differentiation. There were no significant correlations between the expression of VEGF, stage and recurrence of a gastric carcinoma. The microvessel density was significantly higher in the VEGF-positive than the VEGF-negative tumors. Survivals of the VEGF-negative patients were significantly prolonged compared to those of the VEGF-positive patients. CONCLUSION: The results of this study show that the expression of VEGF may be a useful prognostic factor for patients with a gastric adenocarcinoma.

Citations

Citations to this article as recorded by

RETRACTED ARTICLE: KRAS activation in gastric cancer stem-like cells promotes tumor angiogenesis and metastasis
Changhwan Yoon, Jun Lu, Yukyung Jun, Yun-Suhk Suh, Bang-Jin Kim, Jacob E. Till, Jong Hyun Kim, Sara H. Keshavjee, Sandra Ryeom, Sam S. Yoon
BMC Cancer.2023;[Epub] CrossRef
Vascular Endothelial Growth Factor Gene Polymorphisms Associated with Prognosis for Patients with Colorectal Cancer
Jong Gwang Kim, Yee Soo Chae, Sang Kyun Sohn, Yoon Young Cho, Joon Ho Moon, Jae Yong Park, Seoung Woo Jeon, In Taek Lee, Gyu Seog Choi, Soo-Han Jun
Clinical Cancer Research.2008; 14(1): 62. CrossRef

3,934 View
19 Download
2 Crossref

Analysis of 103 Patients with Unknown Primary Carcinoma: Retrospective Study: Jae Jin Lee, Si Young Kim, Kyung Sam Cho, Juhie Lee, Hwi Joong Yoon; J Korean Cancer Assoc. 2001;33(1):1-8.

Abstract PDF: PURPOSE
Unknown primary carcinoma takes up approximately 0.5-10% of the oncology patients evaluated, and the patients have poor survival of between 3 to 11 months. Despite the short survival, certain clinically defined subsets of patients were reported to have a better prognosis. Thus, the objective of this study was to identify prognostic factors.
MATERIALS AND METHODS
The present study was con ducted with 103 patients who were referred from January 1988 to July 1999. The primary end point was survival. The survival curves were estimated using the Kaplan-Meier method and compared using the Log-rank test and Cox's proportional hazards regression analysis.
RESULTS
Most patients had histologic evidence of ade nocarcinoma or squamous cell carcinoma. Univariate and multivariate analyses identified good prognostic factors including performance status (grade 0-2), female and adenocarcinoma with more than moderate level of differentiation. The responders of chemotherapy in squamous cell carcinoma and lung, breast, ovary -estimated- cancer showed good survival rates.
CONCLUSION
Unknown primary carcinoma tended to show a poor prognosis. However, when treatment modality of unknown primary carcinoma is to be determined through the prognostic factors, the patients quality of life can be improved through reducing the treatment side effects and economic burden on the patients.

3,005 View
34 Download

First
Prev
Page of 1
Next
Last

Search